Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

l 11)

-- Announced initiation of a Phase II clinical study with vicriviroc, an

investigational CCR5 antagonist, for use in first-line therapy of adult

treatment-naive HIV-infected patients with R5-type virus only.

(Announced April 15)

First Quarter 2008 Conference Call and Webcast

Schering-Plough will conduct a conference call today at 8 a.m. (EDT) to review the 2008 first quarter results. To listen live to the call, dial 1-877- 565-9664 or 1-706-634-5003 and enter conference ID #40651446. A replay of the call will be available starting at approximately 11 a.m. on April 23 through 5 p.m. on May 22. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID #40651446. A live audio Webcast of the conference call also will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, http://www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the Webcast will be available starting on April 23 through 5 p.m. on May 22.

DISCLOSURE NOTICE: The information in this press release, the comments of Schering-Plough officers during the earnings teleconference/webcast on April 23, 2008, beginning at 8 a.m. (EDT), and other written reports and oral statements made from time to time by the company may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and are based on current expectations or forecasts of future events. You can identify these forward-looking statements by their use of words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "project," "intend," "plan," "potential," "will," and other similar words and terms. In particular, forward-looking statements include statements relating to the comp
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... , March 25, 2015  S&P Capital IQ ... Factual Stock Report coverage on Abattis Bioceuticals Corp ... CSE: ATT): is a specialty biotechnology company with ... licensing and marketing proprietary ingredients, bio-similar compounds, patented ... North America . The company ...
(Date:3/25/2015)... Accelovance, a therapeutically focused contract research organization ... Research Organization" at the upcoming Vaccine Industry Excellence (ViE) ... This is the eighth consecutive year Accelovance has ... for "Best Contract Research Organization" in 2009, 2010, and ... "We,re excited to be a finalist for ...
(Date:3/25/2015)... An increase of awareness related to ... of food nutrients, regulatory changes and concerns related to ... demand for natural astaxanthin over the past few years. ... their capacities to satisfy the rising demand. , ... astaxanthin (used in nutraceuticals, aqua feed, food and beverages ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... AAFS Convention -- With,tomorrow,s release of the Forensics ... Forensic Science Organizations (CFSO) has announced that: , ... be available to the media for comment,on the Forensics ... of,Sciences on Wednesday, February 18th at 1:00 pm EST. ...
... Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical ... the treatment of human viral and other infectious diseases, today ... ended December 31, 2008. At December 31, 2008, Idenix,s cash, ... , , ...
... Even Among Companies Doing Well, Relationships Weaken in Many CountriesNEW ... physicians in four out of the five major European countries ... top marks for effectively delivering key sales and service activities. ... ties with Novartis in the UK and Germany. In ...
Cached Biology Technology:CFSO Calls for Roundtable to Develop National Strategy for Advancing Forensic Sciences in the United States 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 7Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 2Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 3Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 4Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 5Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 6Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 7
(Date:3/10/2015)... PROVO, Utah , March 10, 2015   ... genome interpretation, has been selected by next-generation sequencing company ... provider of whole exome and targeted gene panel interpretation. ... sequencing provider, has adopted the most current technologies to ... of genetic research. The company offers two types of ...
(Date:3/3/2015)... Calif. , March 3, 2015 /PRNewswire/ ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... reproductive medicine, today announced the expansion of ... Research Centers, ("Fred Hutch") Clinical Research ...
(Date:2/25/2015)... 2015  ABC Financial Services (ABC), the leading ... and Fitness Industry, today announced enhancements to their ... latest upgrade includes advances to the agreement section ... via Identity One fingerprint biometrics. The features will ... displays at the International Health, Racquet & Sportsclub ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... expects to fund some 240 top researchers in its ... of grantees follows the 299 researchers who received grants ... In total, 2503 proposals were submitted to the second ... is studying the kidney glomerular ultrafiltration in both health ...
... for Microbiology (ASM) today announced plans to launch mBio ... microbiology research broadly accessible, in mid-2010. The focus of ... spanning the entire spectrum of microbiology and related fields. ... interconnected one in which microbes interact with living and nonliving ...
... circumpolar Arctic research focuses on the physical, direct changes ... and temperature increases. "What,s understudied is the living component ... "Donie" Bret-Harte, associate professor of biology at the University ... be published September 11, 2009 in the journal ...
Cached Biology News:ERC Starting Grant for the researcher of kidney diseases 2American Society for Microbiology to launch new open-access journal 2Scientists seek new emphases in Arctic climate change research 2
... This benchtop ductless exhaust hood ventilates ... safe indoor release of exhaust. Bonded ... Over 28" of vertical clearance (with ... Includes polypropylene spill tray; options include ...
... These versatile enclosures are ... nitrogen or other process ... low-humidity environment. HEPA filtration, ... ionization modules also available, ...
... For the professional, student, or faculty researcher, the ... accelerate your research and improve the quality of ... is the edge that researchers using LI-COR DNA ... years. The 4300 System is a third generation ...
... isolation chamber provides a safe, clean ... pharmaceuticals, in accord with USP-797 requirements. ... (ISO 5) cleanliness conditions in the ... rod and tilt-up front panel for ...
Biology Products: